英国批准了阿巴洛帕拉提德,这是一种治疗绝经后严重骨质疏松症的骨强化药物;可降低脊椎和手臂/手腕骨折的风险. UK approves abaloparatide, a bone-building drug for severe post-menopausal osteoporosis; reduces spine and arm/wrist fracture risks.
英国批准新的骨骼造能药物,aboloparatide,供有严重骨质疏松症和高骨折风险的绝经期后妇女使用。 UK approves new bone-building drug, abaloparatide, for post-menopausal women with severe osteoporosis and high fracture risk. 与抗吸附药物不同的是,巴巴洛二酸盐通过模仿自然荷尔蒙促进骨骼形成。 Different from anti-resorptive drugs, abaloparatide promotes bone formation by mimicking a natural hormone. 临床研究表明,与安慰剂相比,脊椎骨折风险降低88%,手臂/手骨骨折风险降低69%。 Clinical studies show 88% reduced spine fracture risk and 69% reduced arm/wrist fracture risk compared to placebos. 与特立帕肽同样有效，常见的副作用包括恶心、头晕、头痛和心悸。 Equally effective as teriparatide, common side effects include nausea, dizziness, headaches, and heart palpitations.